| Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? MJE Marshall, RJ Stopforth, MS Cragg Frontiers in immunology 8, 1245, 2017 | 181 | 2017 |
| Improving antibody-based cancer therapeutics through glycan engineering X Yu, MJE Marshall, MS Cragg, M Crispin BioDrugs 31, 151-166, 2017 | 65 | 2017 |
| The PI3Kδ-selective inhibitor idelalisib minimally interferes with immune effector function mediated by rituximab or obinutuzumab and significantly augments B cell depletion in … A Palazzo, S Herter, L Grosmaire, R Jones, CR Frey, F Limani, M Bacac, ... The Journal of Immunology 200 (7), 2304-2312, 2018 | 18 | 2018 |
| Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering F Heckel, AH Turaj, H Fisher, HTC Chan, MJE Marshall, O Dadas, ... Communications Biology 5 (1), 229, 2022 | 16 | 2022 |
| Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017; 8: 1245 MJE Marshall, RJ Stopforth, MS Cragg | 4 | 2017 |
| Development of C1q affinity chromatography for the study of C1q–IgG interactions MJE Marshall, A Knaupp, C Spick, I Koese, M Maier, MS Cragg, F Cymer, ... The Journal of Immunology 210 (11), 1837-1848, 2023 | 2 | 2023 |
| Immunological methods to study monoclonal antibody activity in chronic lymphocytic Leukaemia MJ Carter, LN Dahal, KLS Cleary, MJE Marshall, RR French, SA Beers, ... Chronic Lymphocytic Leukemia: Methods and Protocols, 173-184, 2019 | 1 | 2019 |
| Investigation of Fc modifications and their influence on mAb function M Marshall University of Southampton, 2018 | | 2018 |
